Role of metabotropic glutamate receptors in animal models of Parkinson's disease

Polish Journal of Pharmacology

Volumn 55, Issue 6, 2003, Pages 935-950

  Senkowska, Anna ^a   Ossowska, Krystyna ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Animal models; Metabotropic glutamate receptors; Parkinson's disease; Review

Indexed keywords

1 AMINO 1,5 INDANDICARBOXYLIC ACID; 2 (2,3 DICARBOXYCYCLOPROPYL)GLYCINE; 2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 2,4 PYRROLIDINEDICARBOXYLIC ACID; 4 CARBOXY 2 METHYLPHENYLGLYCINE; AMANTADINE; ANTIPARKINSON AGENT; BENSERAZIDE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; DIZOCILPINE; EGLUMETAD; ENTACAPONE; GLUTAMIC ACID; HALOPERIDOL; LEVODOPA; LIGAND; MEMANTINE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PRAMIPEXOLE; RESERPINE; SELEGILINE; UNINDEXED DRUG;

AKINESIA; ATAXIA; BASAL GANGLION; DEGENERATIVE DISEASE; DISEASE MODEL; DRUG EFFICACY; DRUG SELECTIVITY; EXTRAPYRAMIDAL SYSTEM; GAIT DISORDER; HEART ARRHYTHMIA; HUMAN; HYPOKINESIA; MEDICAL LITERATURE; MEMORY DISORDER; MOOD DISORDER; MUSCLE RIGIDITY; NAUSEA AND VOMITING; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PSYCHOSIS; REVIEW; SIGNAL TRANSDUCTION; TREMOR;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; LIGANDS; PARKINSON DISEASE; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION;

EID: 1642503137     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Aguirre J.A., Andbjer B., Gonzalez-Baron S., Hansson A., Stromberg I., Agnati L.F., Fuxe K.: Group I mGluR antagonist AIDA protects nigral DA cells from MPTP-induced injury. NeuroReport, 2001, 12, 2615-2617.
2. Ango F., Prezeau L., Muller T., Tu J.C., Xiao B., Worley P.F., Pin J.P., Bockaert J., Fagni L.: Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. Nature, 2001, 411, 962-965.
3. Angulo J.A.: Involvement of dopamine D1 and D2 receptors in the regulation of proenkephalin mRNA abundance in the striatum and accumbens of the rat brain. J. Neurochem., 1992, 58, 1104-1109.
4. Awad H., Hubert G.W., Smith Y., Levey A.I., Conn P.J.: Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci., 2000, 20, 7871-7879.
5. Battaglia G., Fornai F., Busecti C.L., Aloisi G., Cerrito F., De Blasi A., Melchiorri D., Nicoletti F.: Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J. Neurosci., 2002, 22, 2135-2141.
6. Battaglia G., Monn J.A., Schoepp D.D.: In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci. Lett., 1997, 229, 161-164.
7. Baunez C., Nieoullon A., Amalric M.: In a rat model of parkinsonism, lesions of the subthalamic nucleus reverse increases of reaction time but induce a dramatic premature responding deficit. J. Neurosci., 1995, 15, 6531-6541.
8. Beckstead R.M.: N-methyl-D-aspartate acutely increases proenkephalin mRNA in the rat striatum. Synapse, 1995, 21, 342-347.
9. Bell M.I., Richardson P.J., Lee K.: Functional and molecular characterization of metabotropic glutamate receptors expressed in rat striatal cholinergic interneurons. J. Neurochem., 2002, 81, 142-149.
10. Benquet P., Gee Ch.E., Gerber U.: Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. J. Neurosci., 2002, 22, 9679-9686.
11. Bergman H., Wichman T., De Long M.R.: Reversal of experimental parkinsonism by lesion of the subthalamic nucleus. Science, 1990, 249, 1436-1438.
12. Betarbet R., Sherer T.B., Greenamyre J.T.: Animal models of Parkinson's disease. Bioessays, 2002, 24, 308-318.
13. Biber K., Laurie D.J., Berthele A., Sommer B., Tölle T.R., Gebicke-Härter P.-J., van Calker D., Boddeke H.W.G.M.: Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J. Neurochem., 1999, 72, 1671-1680.
14. Blandini F., Nappi G., Tassorelli C., Martignoni E.: Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog. Neurobiol., 2000, 62, 63-88.
15. Brabet I., Parmentier M.-L., De Colle C., Bockaert J., Acher F., Pin J.-P.: Comparative effect of L-CCG-I, DCG-IV and γ-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes. Neuropharmacology, 1998, 37, 1043-1051.
16. Bradley S.R., Marino M.J., Wittmann M., Rouse S.T., Awad H.: Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia nigra pars reticulata. J. Neurosci., 2000, 20, 3085-3094.
17. Breysse N., Baunez Ch., Spooren W, Gasparini F., Amalric M.: Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J. Neurosci., 2002, 22, 5669-5678.
18. Cartmell J., Schoepp D.D.: Regulation of neurotransmitter release by metabotropic glutamate receptors. J. Neurochem., 2000, 75, 889-907.
19. Danysz W., Frankiewicz T., Parsons C.G.: Glutamatergic receptors. In: Receptors: Structure, Characteristics, Function (Polish). Eds. Nowak J.Z., Zawilska J.B., PWN, Warszawa, 1997, 161-189.
20. Danysz W., Parsons C.G.: Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev., 1998, 50, 597-664.
21. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G.: Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci. Biobehav. Rev., 1997, 21, 455-468.
22. Dawson L., Chadha A., Megalou M., Duty S.: The group II metabotropic glutamate receptor agonist DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Brit. J. Pharmacol., 2000, 129, 541-546.
23. Dingledine R., Borges K., Bowie D., Traynelis S.F., The glutamate receptor ion channels. Pharmacol. Rev., 1999, 51, 8-51.
24. Feany M.B., Bender W.W.: A Drosophila model of Parkinson's disease. Nature, 2000, 404, 394-398.
25. Gerfen CR.: Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci., 2000, 23, Suppl., 64-70.
26. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J.Jr., Sibley D.R.: D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science, 1990, 250, 1429-1432.
27. Gołembiowska K., Konieczny J., Wolfarth S., Ossowska K.: Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats. Neuropharmacology, 2003, 45, 484-492.
28. Gomeza J., Joly C., Kuhn R., Knöpfel T., Bockaert J., Pin J.-P.: The second intracellular loop of mGluR1 cooperates with the other intracellular domains to control coupling to G-protein. J. Biol. Chem., 1996, 274, 2199-2205.
29. Heidinger V., Manzerra P., Wang X.Q., Strasser U., Yu S.-P., Choi D.W., Behrens M.M.: Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons. J. Neurosci., 2002, 22, 5452-5461.
30. Helton D.R., Tizzano J.P., Monn I.A., Schoepp D.D., Kallmann M.J.: Anxiolytic and side-effects profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther., 1998, 284, 651-660.
31. Hubert G.W., Paquet M., Smith Y.: Differential subcellular localization of mGluR1a and mGluR5 in the rat and monkey substantia nigra. J. Neurosci., 2001, 21, 1838-1847.
32. Jankowic J.: New and emerging therapies for Parkinson's disease. Arch. Neurol., 1999, 56, 785-790.
33. Janssens N., Lesage A.S.J.: Glutamate receptor subunit expression in primary neuronal and secondary glial cultures. J. Neurochem., 2001, 77, 1457-1474.
34. Jolkkonen J., Jenner P., Marsden C.D.: Glutamatergic regulation of striatal peptide gene-expression in rats. J.Neural Transm. Parkinsons, 1995, 10, 187-198.
35. Kaur S., Starr M.S.: Differential effects of intrastriatal and intranigral injections of glutamate antagonists on motor behaviour in the reserpine-treated rat. Neuroscience, 1997, 76, 345-354.
36. Kerner J.A., Standaert D.G., Penney J.B.Jr., Young A.B., Landwehrmeyer G.B.: Expression of group one metabotropic glutamate receptor subunit mRNA in neurochemically identified neurons in the rat neostriatum, neocortex and hippocampus. Mol. Brain Res., 1997, 48, 259-269.
37. Konieczny J., Ossowska K., Wolfarth S., Pilc A.: LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn-Schmied. Arch. Pharmacol., 1998, 358, 500-502.
38. Kostowski W.: Disturbances of neurotransmitter processes in Parkinsons' disease. In: Parkinson's Disease (Polish). Eds. Friedman A., α-Medica Press, Bielsko-Biała, 2000, 7-29.
39. Kunishima N., Shimada Y., Tsuji Y., Sato T., Yamamoto M., Kumasaka T., Nakanishi S., Jingami H., Morikawa K.: Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature, 2000, 407, 971-977.
40. Lee R.G.: Pathophysiology of rigidity and akinesia in Parkinson's disease. Eur. Neurol., 1989, 29, Suppl. 1, 13-18.
41. Litschig S., Gasparini F., Rueegg D., Stoehr N., Flor P.J., Vranesic I., Prézeau L., Pin J.-P., Thomsen C., Kuhn R.: CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol. Pharmacol., 1999, 55, 453-461.
42. Lorenc-Koci E., Wardas J., Wolfarth S., Pilc A.: (S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally counteracts parkinsonian-like muscle rigidity in rats. Brain Res., 2001, 903, 177-184.
43. Lorenc-Koci E., Wolfarth S.: Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. Eur. J. Pharmacol., 1999, 385, 39-46.
44. Lorenc-Koci E., Wolfarth S., Ossowska K.: Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity. Exp. Brain Res., 1996, 109, 268-276.
45. Mao L., Wang J.Q.: Group I metabotropic glutamate receptor-mediated calcium signalling and immediate early gene expression in cultured rat striatal neurons. Eur. J. Neurosci., 2003, 17, 741-750.
46. Marti M., Paganini F., Stocchi S., Bianchi C., Beani L., Morari M.: Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release. Eur. J. Neurosci., 2001, 14, 1181-1184.
47. Marti M., Paganini F., Stocchi S., Mela F., Beani L., Bianchi C., Morari M.: Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors. J. Neurochem., 2003, 84, 792-802.
48. Masliah E., Rockenstein E., Veinbergs L, Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L.: Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science, 2000, 287, 1265-1269.
49. Matarredona E.R., Santiago M., Venero J.L., Cano J., Machado A.: Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction. J. Neurochem., 2001, 76, 351-360.
50. Messenger M.J., Dawson L.G., Duty S.: Changes in metabotropic glutamate receptor 1-8 gene expression in the rodent basal ganglia motor loop following lesion of the nigrostriatal tract. Neuropharmacology, 2002, 43, 261-271.
51. Mihm MJ., Schanbacher B.L., Wallace B.L., Wallace L.J., Uretsky N.J, Bauer J.A.: Free 3-nitrotyrosine causes striatal neurodegeneration in vivo. J. Neurosci., 2001, 21, RC149.
52. Moghaddam B., Adams B.W.: Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science, 1998, 281, 1349-1352.
53. 2+ mobilization in dopamine neurons. J. Neurosci., 2003, 23, 149-157.
54. Moroni F., Lombardi G., Thomsen C., Leonardi P., Attucci S., Peruginelli F., Torregrossa S.A., Pellegrini-Giampietro D.E., Luneia R., Pellicciari R.: Pharmacological characterization of 1-aminoindan-1,5-dicarboxylic acid, a potent mGluR1 antagonist. J. Pharmacol. Exp. Ther., 1997, 281, 721-729.
55. Murer M.G., Dziewczapolski G., Salin P., Vila M., Tseng K.Y., Ruberg M., Rubinstein M., Kelly M.A., Grandy D.K., Low M.J., Hirsch E., Raisman-Vozari R., Gershanik O.: The indirect basal ganglia pathway in dopamine D(2) receptor-deficient mice. Neuroscience, 2000, 99, 643-650.
56. Noailles P.A., Villegas M., Ledoux M., Lucas L.R., McEwen B.S., Angulo J.A.: Acute treatment with the N-methyl-D-aspartate receptor antagonist MK-801: effect of concurrent administration of haloperidol or scopolamine on preproenkephalin mRNA levels of the striatum and nucleus accumbens of the rat brain. Neurosci. Lett., 1996, 202, 165-168.
57. Olanow C.W., Tatton W.G.: Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci., 1999, 22, 123-144.
58. O'Leary D.M., Movsesyan V., Vicini S., Faden A.I.: Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Brit. J. Pharmacol., 2000, 131, 1429-1437.
59. Orieux G., François C., Féger J., Hirsch E.C.: Consequences of dopaminergic denervation on the metabolic activity of the cortical neurons projecting to the subthalamic nucleus in the rat. J. Neurosci., 2002, 22, 8762-8770.
60. Ossowska K.: The role of antagonists of glutamatergic receptors in animal models of Parkinson's disease. In: Parkinson's Disease. New Trends and Therapeutic Perspectives (Polish). Ed. Ossowska K., Institute of Pharmacology, Polish Academy of Sciences, Kraków, 1998, 35-53.
61. Ossowska K.: Pharmacology of antiparkinsonian drugs. In: Neuropsychopharmacology. Today and Tomorrow (Polish). Eds. Bijak M., Lasoń W., Institute of Pharmacology, Polish Academy of Sciences, Kraków, 2000, 191-222.
62. Ossowska K., Konieczny J., Pilc A., Wolfarth S.: The striatum as a target for anti-rigor effects of an antagonist of mGluR1, but not an agonist of group II metabotropic glutamate receptors. Brain Res., 2002, 950, 88-94.
63. Ossowska K., Konieczny J., Wolfarth S., Wierońska J., Pilc A.: Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology, 2001, 41, 413-420.
64. Ossowska K., Wardas J., Pietraszek M., Konieczny J., Wolfarth S.: The striopallidal pathway is involved in antiparkinsonian-like effects of the blockade of group I metabotropic glutamate receptors in rats. Neurosci. Lett., 2003, 342, 21-24.
65. Pagano A., Rüegg D., Litschig S., Stoehr N., Stierlin C., Heinrich M., Floersheim P., Prezeau L., Carroll F., Pin J.-P., Cambria A., Vranesic I., Flor P.J., Gasparini F., Kuhn R.: The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclo-propan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J. Biol. Chem., 2000, 275, 33750-33758.
66. Page G., Peeters M., Najimi M., Maloteaux J.-M., Hermans E.: Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes. J. Neurochem., 2001, 76, 1282-1290.
67. Pałucha A., Pilc A.: Metabotropic glutamatergic receptors (mGluR). In: Excitatory Amino Acids 2000 - Physiological and Pathological Aspects, and the Therapy of Neuropsychiatric Diseases (Polish). XVII Winter School of Institute of Pharmacology, Polish Academy of Sciences, Przegorzały 2000. Eds. Pilc A., Popik P., Institute of Pharmacology, Polish Academy of Sciences, Kraków, 2000, 53-63.
68. Parelkar N.K., Wang J.Q.: Preproenkephalin mRNA expression in rat dorsal striatum induced by selective activation of metabotropic glutamate receptor subtype-5. Synapse, 2003, 47, 255-261.
69. Patel N.K., Heywood P., O'Sullivan K., McCarter R., Love S., Gill S.S.: Unilateral subthalamotomy in the treatment of Parkinson's disease. Brain, 2003, 126, 1136-1145.
70. Petralia R.S., Wang Y.X., Niedzielski A.S., Wenthold R.J.: The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience, 1996, 71, 949-976.
71. Phillips T., Rees S., Augood S., Waldvogel H., Faull R., Svendsen C., Emson P.: Localization of metabotropic glutamate receptor type 2 in the human brain. Neuroscience, 2000, 95, 1139-1156.
72. Pisani A., Calabresi P., Centonze D., Bernardi G.: Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. Brit. J. Pharmacol., 1997, 120, 1007-1014.
73. Popik P., Kozela E., Pilc A.: Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice. Brit. J. Pharmacol., 2000, 130, 1425-1431.
74. Ray K.: Structure-function relationships of the family 3 G-protein-coupled receptors. Int. Arch. Biosci., 2001, 1027-1035.
75. Saugstad J.A., Yang S., Pohl J., Hall R.A., Conn P.J.: Interaction between metabotropic glutamate receptor 7 and alpha tubulin. J. Neurochem., 2002, 80, 980-988.
76. Schapira A.H.V., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D.: Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem., 1990, 54, 823-827.
77. Schmidt W. J., Bubser M.: Anticataleptic effects of the N-methyl-D-aspartate antagonist MK 801 in rats. Pharmacol. Biochem. Behav., 1989, 32, 621-623.
78. Shigemoto R., Nomura S., Ohishi H., Sugihara H., Nakanishi S., Mizuno N.: Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci. Lett., 1993, 163, 53-57.
79. Shimizu E., Tang Y.-P., Rampon C., Tsien J.Z.: NMDA receptor-dependent synaptic reinforcement as a crucial process for memory consolidation. Science, 2000, 290, 1170-1174.
80. Spooren W.P.J.M., Gasparini F., Bergmann R., Kuhn R.: Effects of the prototypical mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur. J. Pharmacol., 2000, 406, 403-410.
81. Tanabe Y., Nomura A., Masu M., Shigemoto R., Mizuno N., Nakanishi S.: Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. J. Neurosci., 1993, 13, 1372-1378.
82. Tatarczyńska E., Kłodzińska A., Chojnacka-Wójcik E., Pałucha A., Gasparini F., Kuhn R., Pilc A.: Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Brit. J. Pharmacol., 2001, 132, 1423-1430.
83. Testa C.M., Standaert D.G., Young A.B., Penney J.B. Jr.: Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J. Neurosci., 1994, 14, 3005-3018.
84. Thiruchelvam M., Richfield E.K., Baggs R.B., Tank A.W., Cory-Slechta D.A.: The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci., 2000, 20, 9207-9214.
85. Venero J.L., Santiago M., Tomas-Camardiel M., Matarredona E.R., Cano J., Machado A.: DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury. Neuroscience, 2002, 113, 857-869.
86. Wade T.V., Schneider J.S.: Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs. J. Neurosci., 2001, 21, 4901-4907.
87. Wardas J., Pietraszek M., Wolfarth S., Ossowska K.: The role of metabotropic glutamate receptors in regulation of striatal proenkephalin expression: implications for the therapy of Parkinson's disease. Neuroscience, in press.
88. Wittmann M., Marino M.J., Conn P.J.: Dopamine modulates the function of group II and group III metabotropic glutamate receptors in the substantia nigra pars reticulata. J. Pharmacol. Exp. Ther., 2002, 302, 433-441.